Cancer Genetics Inc (CGIX)

[chmcnfunds]

Interesting but unconfirmed summary:

$CGIX: What’s Holding It Back?
Posted on January 27, 2016 | By Dr Kanak Kanti De | Leave a response
This paragraph from a subscriber: Continued positive CGIX developments with their comprehensive Immuno-Oncology Testing Portfolio; their Nov $4 secondary offering hurt us longs but with positive 3Q earnings and 2015 headlines (below), I remain steadfastly long. Basics: 26M cap, 52 wk hi/lo $12.75/$1.90. 2015 highlights: ICON partnership; Response Genetics acquisition (included 3 patents); third patent awarded for FHACT test; $1M net cash from NOL tax credit transfer, Frigate Ventures 6.5% stake; SWK Holdings 6.9% stake; signed as in-network provider with Harvard Pilgrim Healthcare (HPHC) and Blue Cross (BCBS) bringing total lives covered to 50M; CLL trial contract; Moffitt research collaboration.) The consensus sales forecast for 2016 sales is more than $36 million, which means that the stock is trading at less than 1x sales. I believe it will surpass its current $7 target. The real question we longs continuously ask is when?

https://drkkd.com/3312/cgix-whats-holding-it-back/

______________________________________________-

CGIX